Bristol Myers Squibb (BMY) Non-Current Assets (2009 - 2026)

Bristol Myers Squibb has disclosed Non-Current Assets across 18 years of filings, most recently posting $59.3 billion for Q1 2026.

• In Q1 2026, Non-Current Assets fell 3.85% year-over-year to $59.3 billion; the TTM figure through Mar 2026 stood at $242.6 billion (down 5.89% YoY), while the FY2025 annual figure was $60.6 billion, down 3.46% from the prior year.
• Non-Current Assets eased to $59.3 billion in Q1 2026, from $60.6 billion in the prior quarter.
• Over the last five years, Non-Current Assets for BMY reached as high as $72.9 billion in Q1 2022 and fell as low as $59.3 billion in Q1 2026.
• The 5-year median for Non-Current Assets is $65.4 billion (2023), against an average of $65.6 billion.
• Annual changes were most pronounced in 2022 — Non-Current Assets slipped 14.55% — and 2024, when it increased 4.71%.
• A 5-year view of Non-Current Assets shows it stood at $69.5 billion in 2022, then declined by 8.85% to $63.4 billion in 2023, then declined by 0.89% to $62.8 billion in 2024, then declined by 3.46% to $60.6 billion in 2025, then decreased by 2.28% to $59.3 billion in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $59.3 billion, $60.6 billion, and $61.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.